FDA puts up a red light for Pas­sage Bio’s first gene ther­a­py pro­gram, de­lay­ing a pro­gram from James Wilson's group at Penn

Gene ther­a­py pi­o­neer James Wil­son spear­head­ed an­i­mal stud­ies demon­strat­ing the po­ten­tial of new treat­ments in­ject­ed di­rect­ly in­to the brain, look­ing to jump­start a once-and-done fix …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER